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Purpose/Objectives: Current Radiation Therapy Oncology Group (RTOG) guidelines for pelvic
radiation therapy are based on general anatomic boundaries. Sentinel lymph node (SLN) imaging
can identify potential sites of lymph node involvement. We sought to determine how tailored
radiation therapy ﬁelds for prostate cancer would compare to standard RTOG-based ﬁelds. Such
individualized radiation therapy could prioritize the most important areas to irradiate while
potentially avoiding coverage in areas where critical structures would be overdosed. Individualized
radiation therapy could therefore increase the therapeutic index of pelvic radiation therapy.
Methods and materials: Ten intermediate or high-risk prostate cancer patients received androgen
deprivation therapy with deﬁnitive radiation therapy, including an SLN imagingetailored elective
nodal volume (ENV). For dosimetric analyses, the ENV was recontoured using RTOG guidelines
(RTOG_ENV) and on SLNs alone (SLN_ENV). Separate intensity modulated radiation therapy
(IMRT) plans were optimized using RTOG_ENV and SLN_ENV for each patient. Dosimetric
comparisons for these IMRT plans were performed for each patient. Dose differences to targets and
critical structures among the different IMRT plans were calculated. Distributions of dose
parameters were analyzed using non-parametric methods.
Results: Sixty percent of patients had SLNs outside of the RTOG_ENV. The larger volume IMRT
plans covering SLN imagingetailored elective nodal volume exhibited no signiﬁcant dose dif-
ferences versus plans covering RTOG_ENV. IMRT plans covering only the SLNs had signiﬁcantly
lower doses to bowel and femoral heads.Conﬂicts of interest: None.
* Corresponding author. Department of Radiation Oncology, University of California, San Francisco, 1600 Divisadero Street, Suite H103, San
Francisco, CA 94115.
E-mail addresses: MRoach@radonc.ucsf.edu (M. Roach).
http://dx.doi.org/10.1016/j.adro.2015.11.004
2452-1094/Copyright  2016 the Authors. Published by Elsevier Inc. on behalf of the American Society for Radiation Oncology. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
52 C.P. Chen et al Advances in Radiation Oncology: JanuaryeMarch 2016Conclusions: SLN-guided pelvic radiation therapy can be used to either treat the most critical
nodes only or as an addition to RTOG guided pelvic radiation therapy to ensure that the most
important nodes are included.
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Median Range
Age of diagnosis, y 74 (56-81)
Clinical stage (T1c-T3a)
Gleason score 7 (7-9)
Pretreatment prostate-speciﬁc
antigen, ng/mL
14.7 (4.8-70)
Body mass index 29.9 (24.6-41.9)Introduction
High- and intermediate-risk prostate cancer (PCa) pa-
tients have increased risk of lymph node involvement
(LNI). Recent studies suggest that the incidence of LNI is
underestimated.1 One recent study of high-risk PCa
treated with radical prostatectomy and extended pelvic
lymph node and retroperitoneal lymph node dissection
showed that 78% of patients had both common and para-
aortic involvement.2 Pathological evaluation of surgical
specimens may also underestimate LNI as reverse
transcriptase-polymerase chain reaction detects lymph
node micrometastases in w30% of cases.3 In addition,
conventional noninvasive imaging with computed to-
mography (CT) and magnetic resonance imaging has low
sensitivity.4,5 Therefore, although accurate identiﬁcation
of LNI in PCa is critical, there is currently no sensitive
and accurate means to determine nodal status in patients
undergoing radiation therapy (RT).
Sentinel lymph node (SLN) imaging has been suc-
cessfully applied to evaluate LNI in other cancers, such as
breast cancer.6 Although SLN imaging is not a key
component of treatment in PCa, several studies have used
SLN imaging to guide more accurate nodal dissections.7,8
Of note, SLNs are found to reside outside of normally
dissected areas in 30% to 40% of cases.8 Therefore, SLN
imaging offers an attractive modality to accurately iden-
tify potential sites of LNI in PCa before deﬁnitive
treatment.
One treatment strategy for select intermediate- and
high-risk PCa patients is deﬁnitive RT, including whole-
pelvis RT (WPRT) with androgen deprivation.9 The role
of WPRT is controversial, but the goal is to sterilize
microscopic disease in patients with pelvic LNI. The
Radiation Therapy Oncology Group (RTOG) 9413 trial
initially demonstrated an advantage for neoadjuvant hor-
mone therapy and WPRT.9 The progression-free survival
beneﬁt seen in RTOG 9413 remains controversial.1 The
recent French Genitourinary Tumor Group Trial-01 found
no survival beneﬁt for WPRT,10 but the study may have
been too small (nZ 444); only 45% of the patients had a
risk of nodal involvement greater than 15%, and the ﬁelds
would have been described as “mini-pelvis” rather than
whole pelvis according to the RTOG 9413 protocol.1
There is evidence supporting WPRT for high-risk PCa,1
and several ongoing trials seek to further deﬁne the role
of WPRT, including RTOG 0924 and Prostate and PelvisVersus Prostate Alone Treatment for Locally Advanced
Prostate Cancer (PIVOTAL) phase 2 trial.
With accurate identiﬁcation of potential lymph node
metastases, elective WPRT in PCa may be better planned
and delivered. However, dosimetric and toxicity infor-
mation on SLN-guided image guided RT (IMRT) for PCa
patients is limited. We thus present a study incorporating
SLN imaging guided IMRT for PCa patients to compare
its dosimetric characteristics with RTOG-based IMRT
plans.
Methods and Materials
Patients
Ten patients at our institution were serially accrued.
Eligibility criteria include pathologically conﬁrmed cN0
cM0 PCa with Gleason score 7 and LNI risk 15%
based on the Roach formula. Patients who had prior
prostatectomy or pelvic RT were excluded. Patient and
tumor characteristics are summarized in Table 1. Clinical
stages of patients were as follows: 2 T1c, 4 T2a/b, and 4
T3a. Six patients had Gleason score of 3þ4, 3 Gleason
4þ3, and 1Gleason 4þ5.
SLN mapping and treatment
Before RT, all patients had gold marker ﬁducials placed
into the prostate. During ﬁducial placement, lymphatic
drainage mapping was performed as described previously.
Brieﬂy, ﬁltered Tc-sulfur nanocolloid was divided equally
into 6 fractions and administered evenly into three locations
(apex, mid-gland, and base) for each lobe. After 1.5 to 3
hours of tracer administration, a combined single-photon
emission computed tomography (SPECT)/CT was per-
formed.11 Reportable adverse events were communicated 1
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morbidity of SLN imaging were tabulated.
Patients received at least 4 months of androgen depri-
vation and were treated with deﬁnitive RT, including
elective nodal irradiation. For RT, patients received a
planning CT after undergoing SLN mapping. Planning CT
image sets were registered to the SPECT/CT image sets
using rigid registration with MIMVista (version 4.1.2,
Cleveland, OH). Afterwards, manual segmentation of
SLNs was performed. SLNs were contoured on the plan-
ningCTonlywhen therewas aCT correlate. In addition, the
nodal regions that included the SLNs were contoured in a
similar fashion as suggested by RTOG, whereby a 7-mm
radial margin was used. All patients had 3 sets of nodal
volumes generated. First, the RTOG-based guidelines were
used to create RTOG_ENV.12 Next, SLN-only plans were
generated using the sentinel nodes and a 7-mm radial
margin around the sentinel nodes (SLN_ENV). The ﬁnal
and largest nodal volume generated is the Tx_ENV, which
is a nodal volume generated using RTOG guidelines plus
the SLN and a 7-mm margin. Therefore, Tx_ENV is the
summation of RTOG_ENV and SLN_ENV. All nodal
volumes were modiﬁed by excluding bowel and bone.
Organs at risk (OARs) were contoured similar to RTOG
guidelines. The bowel was the entire abdominal cavity with
the exclusion of muscle, bone, and blood vessels. The su-
perior border of the bowel contour was 1.5 cm above the
planning target volume. The rectum was contoured from
the anus to the rectosigmoid ﬂexure. The femur was con-
toured for the ischial tuberosity to the top of the ball of the
femur. The bladder was contoured in its entirety. Seg-
mentation of target and OAR structures was performed and
reviewed by the treating physician.
All patients were planned and treated in the supine
position. An optimized IMRT plan was created for each
patient using ADAC Pinnacle (Version 8.0d, Philips,
Madison, WI). Patients received either (1) 78 Gy at 2 Gy
per fraction to the prostate and 45 Gy at 1.8 Gy per
fraction to Tx_ENV or (2) 45 Gy at 1.8 Gy per fraction to
the prostate and Tx_ENV followed by a HDR brachy-
therapy prostate boost of 19 Gy in 2 fractions or 15 Gy in
1 fraction. This report only considers the dosimetry dur-
ing the initial pelvic nodal treatment, so the dosimetry
resulting from boost treatment is not reported.Dosimetric analysis
To compare the dosimetric characteristics of SLN
imaging guided pelvic IMRT to standard RTOG-based
IMRT plans, three optimized IMRT plans were created,
one using Tx_ENV (the largest volume), a second using
RTOG_ENV, and a third using SLN_ENV (the smallest
volume).
Dosimetric analyses were performed comparing dosi-
metric values and relevant dose-volumehistogramparametersamong the three IMRT plans. Mean, maximum, and mini-
mum dose to targets and OARs were recorded. OARs were
also assessedby the relative percent volumes receiving50Gy,
45 Gy, 40 Gy, and 20 Gy (rV50, rV45, rV40, and rV20,
respectively) and absolute volume receiving 45 Gy, 40 Gy,
and 20 Gy (aV45, aV40, and aV20).
Statistics
Descriptive statistics were calculated for doses to target
volumes and OARs. Because of the sample size, the
distributions of dosing parameters were analyzed using
nonparametric methods for dependent measures. The
Friedman test was used to compare the distributions of the
mean, maximum, and minimum doses for targets and
OARs for the three treatment plans.13 If overall statistical
signiﬁcance was determined, then pairwise comparisons
were tested. This was carried out based upon the Fried-
man test using the sum of the ranks for each group to
identify which plans differed. Signiﬁcance was deﬁned as
a probability value less than .05 and no adjustments were
made for multiple testing.
Results
SLN mapping and elective nodal volumes
All patients had at least one SLN identiﬁed. SLNs were
identiﬁed in the internal/external iliac nodal basins in all
cases, common iliacs in 50%, and para-aortics in 50%.
Thirty percent of patients had both common iliac and
para-aortic SLNs. In regard to SLN coverage, standard
RTOG nodal volumes encompassed all identiﬁed SLNs in
only 30% of cases. SLN imaging information altered the
Tx_ENV in 60% of cases. In one case, the physician did
not increase the volume as suggested by SLN imaging
because of concern of potential acute morbidity. The
median percent increase with respect to the standard
RTOG ENV was 97.9% (range, 40.2%-152.4%). Figure 1
provides an illustrative case. When SLNs were located
outside of standard RTOG nodal volumes, the median
distance from the SLNs to the RTOG nodal volumes was
6.2 cm (range, 0.5-11.2 cm).
Dosimetric analyses
Figure 2 presents illustrative IMRT plans covering
Tx_ENV, RTOG_ENV, and SLN_ENV. Signiﬁcant dif-
ferences among the distributions of the mean, maximum,
and minimum dose were observed. Table 2 summarizes
the signiﬁcant comparisons.
Overall, there is no evidence found suggesting a dif-
ference for mean dose between plans with Tx_ENV and
RTOG_ENV. However, the mean doses for OARs were
Figure 1 Illustrative case in which standard pelvic nodal volumes fail to include identiﬁed sentinel lymph nodes (SLNs). (A) Ra-
diation Therapy Oncology Group elective nodal volume (ENV) (green) fails to cover right proximal common iliac SLN (red arrow). (B)
Treated ENV (blue) covers all identiﬁed SLNs.
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Tx_ENV or RTOG. The median difference in mean dose
for targets was often less than 1 Gy (Table 3). Small dif-
ferences of <2 Gy were seen for most OARs, including
bladder and rectum. However, increased mean dose to the
bowel and femoral heads (FHs) occurred in plans with
Tx_ENV and RTOG_ENV as compared with plans with
the smaller SLN_ENV. The mean dose to bowel was
higher for 8 of 10 patients with Tx_ENV plan versus either
of the other two plans and signiﬁcantly higher compared
with plans using SLN_ENV. The median difference in
mean dose to either the right or left FH was >3 Gy when
using plans with Tx_ENV or RTOG_ENV versus with
SLN_ENV. Although there were increased bowel and FH
doses, the total dose to these structures were still within our
institution’s dose constraints.
A similar pattern was observed for differences between
plans in maximum dose and minimum dose. Higher
maximum and minimum doses are delivered to the bowel
and FH when using Tx_ENV compared with SLN_ENV.
As for other OARs, although statistically signiﬁcant,
differences were small and usually <2 Gy. Overall, theFigure 2 Illustrative case comparing image guided radiation therap
Therapy Oncology Group (RTOG)_ENV, or sentinel lymph node (SLN
identiﬁed. (B) RTOG_ENV is based on consensus RTOG guidelines
underdosed. (C) SLN_ENV only includes SLNs without the nearby n
minimizing dose to OARs. The yellow isodose line represents 45 Gymaximum and minimum doses to OARs were lower with
plans with SLN_ENV, but no signiﬁcant differences in
maximum or minimum dose were observed between plans
with Tx_ENV and RTOG_ENV (see Table 4). Analysis
of dose-volume histogram parameters again does not
suggest any differences between plans with Tx_ENV
versus those with RTOG_ENV, whereas consistent dose
differences are observed for bowel and FH (Table 5).
In regard to target structures, although statistically
signiﬁcant differences in mean, maximum, and minimum
dose occurred for the seminal vesicles, prostate, and ENV,
the dose differences were often small (<1 Gy). Overall,
target structures had few dose differences. Again, no
signiﬁcant dose differences in target structures occurred
between Tx_ENV and RTOG_ENV.
Toxicity
SLN imaging morbidity was minimal with only 2 pa-
tients noting prostate pain during or 1 week after the
procedure. However, the patients also had gold marker
seed placement at the time of the colloid injection, so they plan with treated elective nodal volume (Tx_ENV), Radiation
)_ENV. (A) Tx_ENV includes nodal regions where SLNs were
and, in this case, fails to cover a proximal right SLN, which is
odal region, which allows for good coverage of all targets while
; the orange isodose line represents 54 Gy.
Table 2 Median differences in mean doses for target and critical structures
Target/OAR Tx_ENV (range in Gy) RTOG_ENV (range in Gy) SLN_ENV (range in Gy)
Prostate 48.47 (46.87-58.63) 49.36 (46.88-59.25) 48.9 (46.8-59.29)
Seminal vesicle 48.26 (46.59-57.62) 49.21 (46.70-57.91) 49.05 (46.87-58.07)
Elective nodal volume 48.23 (46.87-52.03) 48.42 (46.98-51.54) 47.61 (46.54-52.58)
Bladder 29.68 (26.55-35.92) 30.5 (25.71-34.58) 28.52 (19.40-33.80)
Rectum 25.74 (20.72-28.99) 26.24 (20.89-30.63) 24.36 (20.42-29.24)
Right femoral head 27.33 (20.27-34.50) 22.86 (17.60-29.21) 20.75 (12.88-34.25)
Left femoral head 27.41 (21.97-33.54) 25.08 (18.79-33.75) 17.30 (11.64-30.53)
Bowel 12.78 (5.01-22.39) 7.39 (4.17-12.58) 4.98 (0.48-13.47)
OAR, organs at risk; RTOG_ENV, Radiation Therapy Oncology Group guidelines–based elective nodal volume; SLN_ENV, sentinel lymph node
elective nodal volume; TX_ENV, elective nodal volume generated using RTOG guidelines plus the SLN and a 7-mm margin.
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episodes of fever, hematuria, hematospermia, and rectal
bleeding were reported. In regard to RT, no grade 3 or
higher acute gastrointestinal or genitourinary toxicity
were noted.Discussion
In our study, we determined the feasibility and dosi-
metric consequences of incorporating SLN imaging in-
formation into IMRT plans for PCa. SLN imaging has
low morbidity and resulted in modiﬁcation of ENV in a
signiﬁcant proportion of cases. Our analyses did not
suggest any differences between IMRT plans with
Tx_ENV versus those with RTOG_ENV. However, plans
using SLN_ENV exhibited lower bowel and femoral head
doses. Overall, SLN guided IMRT is feasible with mini-
mal dosimetric impact except to bowel and femoral heads.
The clinical signiﬁcance of dose differences to these
structures remains to be clariﬁed with further follow-up.
This study importantly demonstrates that SLN guided
IMRT should likely have toxicity proﬁles similar to thatTable 3 Median difference in mean dose between plans for targe
Target/OAR Tx vs RTOG
Prostate 0.05 (1.94 to 0.80)
Seminal vesicle 0.23 (1.35 to 0.72)
P>.05
Elective nodal volume 0.12 (1.09 to 0.94)
Bladder 0.53 (1.10 to 1.32)
P>.05
Rectum 0.85 (2.41 to 1.01)
P>.05
Right femoral head 3.72 (2.33-11.64)
P>.05
Left femoral head 3.31 (2.12 to 5.41)
P>.05
Bowel 4.80 (0.22 to 12.80)
P>.05
OAR, organs at risk. P values reﬂect differences between the largest noda
recommended (RTOG); Tx vs sentinel lymph node only volume (SLN); andseen in prior studies using WPRT and a four-ﬁeld RT
technique. From RTOG 9413, only an increased rate of
late gastrointestinal toxicity 3 was seen with WPRT þ
neoadjuvant hormone therapy.14 In RTOG 9413, the ENV
included the standard consensus RTOG nodal regions, but
SLN guided IMRT would incorporate Tx_ENV that could
be larger than RTOG-based ENV. This could result in
larger bowel aV45. However, IMRT can provide superior
dose sparing to OARs and thus potentially decrease tox-
icities.15,16 On the other hand, if only SLNs are irradiated,
then lower bowel doses would be expected. Therefore,
application of SLN imaging guided IMRT would likely
result in a comparable if not lower toxicity proﬁle than
that seen in RTOG 9413.
Additionally, some argue that current patients may
have lower LNI than historical cohorts.17 Hence, elective
pelvic RT to large ENV may not be needed. In our study,
IMRT plans covering SLN_ENV address the likely areas
of LNI while reducing bowel and femoral head doses.
Nonetheless, such an approach may not be ideal because
there is an increased chance of involved non-SLNs in the
same drainage region when positive SLNs were detected
in surgical series.18t or OAR
Tx vs SLN RTOG vs SLN
0.08 (1.51 to 0.50) 0.04 (1.24 to 0.84)
0.40 (1.15 to 0.52)
P [ .019
0.05 (0.96 to 0.53)
P>.05
0.39 (0.70 to 3.81) 0.52 (1.04 to 3.87)
1.49 (0.36-7.15)
P< .01
1.82 (0.57-6.31)
P< .01
0.51 (1.02 to 2.86)
P>.05
1.62 (0.25 to 3.66)
P< .01
7.98 (2.39 to 11.17)
P< .013
3.05 (5.04 to 7.62)
P>.05
7.53 (1.10-12.42)
P< .013
5.00 (2.83-7.90)
P [ .026
8.89 (2.79 to 14.61)
P< .01
2.15 (2.56 to 6.71)
P>.05
l volume generated (Tx) vs the Radiation Therapy Oncology Group
RTOG vs SLN, respectively.
Table 4 Pairwise dose differences among plansa
Target/OAR Mean dose Maximum dose Minimum dose
Tx vs
RTOG
TX vs
SLN
RTOG
vs SLN
Tx vs
RTOG
TX vs
SLN
RTOG
vs SLN
Tx vs
RTOG
TX vs
SLN
RTOG
vs SLN
Prostate X
SV X
LN X X X X
Bladder X X X X
Rectum X X X
Right Femoral Head X X X
Left Femoral Head X X X X X
Bowel X X X X
LN, lymph node; RTOG, Radiation Therapy Oncology Group; RTOG_ENV, RTOG-based elective nodal volume; RTOG vs SLN, dose from plan
with RTOG_ENV minus dose from plan with SLN_ENV; SLN_ENV, sentinel lymph node only volume; SV, seminal vesicles; Tx_ENV, treated
elective nodal volume; Tx vs RTOG, dose from plan with Tx_ENV minus dose from plan with RTOG_ENV; Tx vs SLN, dose from plan with
Tx_ENV minus dose from plan with SLN_ENV.
a Statistically signiﬁcant comparisons are marked with X. P<.05.
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comparison to prior studies.8,15,19 Ganswindt and co-
workers found common iliac and para-aortic SLNs in aboutTable 5 Dose-volume histogram parameter comparison for critica
Tx vs RTOG T
Bladder
rV50 (%) NS N
rV45 (%) NS N
rV40 (%) NS N
aV40 (mL) NS N
Rectum
rV50 (%) NS N
rV45 (%) NS N
rV20 (%) NS N
aV20 (mL) NS N
Right femoral head
rV50 (%) NS N
aV50 (mL) NS N
rV20 (%) NS 2
aV20 (mL) NS 2
Left femoral head
rV50 (%) NS N
aV50 (mL) NS N
rV20 (%) NS 4
aV20 (mL) NS 3
Bowel
aV50 (mL) NS 0
aV45 (mL) NS 5
Median difference and range shown for each dosimetric parameter. Values a
NS, not signiﬁcant; RTOG, Radiation Therapy Oncology Group; RTOG_ENV
only volume; Tx_ENV, treated elective nodal volume; Tx vs RTOG, dose fro
SLN, dose from plan with Tx_ENV minus dose from plan with SLN_ENV.48% and 23% to 25% of patients, respectively.19 However,
we observed a higher proportion of SLNs in the common
iliacs (50%) and para-aortics (50%). Factors that may havel structures
x vs SLN RTOG vs SLN
S NS
S NS
S NS
S NS
S NS
S NS
S NS
S NS
S NS
S NS
9.57 (0.60 to 86.93%)
P< .01
NS
5.20 (0.45 to 74.78)
P< .01
NS
S NS
S NS
0.70 (11.06-85.90%)
P< .01
26.76 (0.28-85.96%)
P Z .019
3.89 (0.08 to 64.30)
P< .01
NS
.95 (0-28.14)
P [ .037
0.67 (0-20.39)
P Z .037
9.15 (8.15-117.26)
P< .01
43.99 (2.88-104.27)
P Z .019
re only shown for those with statistically signiﬁcant differences.
, RTOG-based elective nodal volume; SLN_ENV, sentinel lymph node
m plan with Tx_ENV minus dose from plan with RTOG_ENV; Tx vs
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size of 10 versus their 61 patients and their inclusion of
10% patients having Gleason score of 6 or less. Also, our
alternative technique using 99mTc-sulfur nanocolloid for
prostate lymphoscintigraphy rather than the 99mTc-Nano-
coll may have resulted in a different tracer distribution.
Nonetheless, our ultimate conclusions were similar. In our
study, 70% of patients would have inadequate coverage of
all identiﬁed SLNs, which is comparable to a prior study.15
Few studies incorporate SLN imaging into RT planning.
One approach involves a SPECT-derived atlas for SLNs.19
This atlas can be used to modify or enhance RTOG-based
consensus nodal volumes. Alternatively, an IMRT
approach treating patients in the prone position and using a
clinical target volume that receives 50 Gy that was
expanded to include identiﬁed SLNs was proposed. Seven
SLNs were not included to avoid an “unacceptable” in-
crease in treatment volume.15 Although our technique
differed in patient positioning, our treatment inclusion of
SLNs and ﬁndings are similar. Nonetheless, both our study
and prior studies have been small in regard to patient
number and will need further validation.
Another limitation is that SLN imaging cannot conﬁrm
pathological LNI. Preoperative SLN imaging has found
false-positive nodal staging.20 In a more recent report, pre-
operative SLN imaging led to a false-negative rate of 10%.21
Nonetheless, in a larger study of high-risk PCa patients, SLN
imaging had a positive predictive value of 72.3% and a
negative predictive value of 98.5%.18 Therefore, SLN im-
aging has potential to detect LNI, but given the variability of
published results, another diagnostic modality may be
needed to help conﬁrm the presence of LNI.
Conclusions
Several contouring guidelines have been suggested,
most recently by the Royal Marsden Hospital,22 but no
existing guideline incorporates patient-speciﬁc nodal
drainage pathways. The RTOG-based guidelines result in
nodal volumes that may omit critical drainage pathways
in some patients. Despite enlarging the elective pelvic
nodal region in a signiﬁcant proportion of cases, SLN-
guided RT (Tx_ENV) is feasible with no signiﬁcant dif-
ference in doses to OARs. Toxicity from SLN guided
IMRT should be comparable to current standard RTOG-
based IMRT plans. In fact, in select cases with bowel
comorbidities, SLN-only RT may offer lower bowel
doses. The results warrant further follow-up and future
consideration for clinical trials to compare the long-term
efﬁcacy of SLN-guided RT with standard treatment ﬁelds.
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